HIV in Remission After U.S. Woman Receives Haplo-Cord Transplant

A middle-aged woman with HIV who received a cord blood hematopoietic cell transplant to treat acute myeloid ...

FEBRUARY 16, 2022

FDA Approves Livtencity for Post-Transplant Recipients With Refractory CMV

The FDA approved maribavir (Livtencity, Takeda) as the first drug for treating patients 12 years of age and older ...

NOVEMBER 24, 2021

Speedier Busulfan Washout A Plus in HCT Conditioning?

The washout period between the last dose of metronidazole and the first dose of the alkylating agent busulfan can ...

JULY 13, 2021

Fostering Global Antimicrobial Stewardship for HCT Patients

A multidisciplinary team at The Ohio State University has implemented a pharmacist mentoring program to assist ...

NOVEMBER 13, 2018

FDA Warns of Higher Risk for Ca Relapse With Long-Term Azithromycin in Allo-HCT Pts

Results of a clinical study, which attempted to prevent this serious lung condition with azithromycin prophylaxis, ...

AUGUST 10, 2018

Trial Is Assessing KRd Versus KCd in Newly Diagnosed MM Pts

Chicago—As an induction therapy in newly diagnosed, relatively young patients with multiple myeloma (MM), ...

JUNE 30, 2017

How I Manage Allo-HCT for Multiple Myeloma

Despite the availability of so-called novel therapies for induction, consolidation, and maintenance in combination ...

FEBRUARY 3, 2017

Inpatient Palliative Intervention Benefits Patients Undergoing HCT

San Francisco—Inpatient palliative care improves quality of life (QOL), symptom burden, depression and ...

OCTOBER 6, 2016